NASDAQ:SYRS

Syros Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy SYRS

*Your capital is at risk

$0.0002

+0 (+0%)

At Close: Jun 02, 2026

Syros Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 28.21. In total, the insiders bought 1.07M and sold 1.21M SYRS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	28.21
● Buy	1.07M shares
● Sell	1.21M shares
74% Buy Activity Weak Negative Correlation
Buy Signal Medium Confidence Jun 01, 2026 Analysis Breakdown: Supported by a positive Insider Power Score of 28.21. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Sep 16, 2024 Buy	Common Stock M-Exempt	Young Richard A Director	Director	2 667 Value: $5K
Sep 16, 2024 Buy	Restricted Stock Units M-Exempt	Young Richard A Director	Director	2 667 Value: $5K
Sep 16, 2024 Buy	Restricted Stock Units M-Exempt	Young Richard A Director	Director	2 667 Value: $5K
Sep 16, 2024 Buy	Common Stock M-Exempt	Young Richard A Director	Director	2 667 Value: $5K
Sep 16, 2024 Buy	Restricted Stock Units M-Exempt	Akkaraju Srinivas Director	Director	2 667 Value: $5K
Sep 16, 2024 Buy	Common Stock M-Exempt	Akkaraju Srinivas Director	Director	2 667 Value: $5K
Sep 12, 2024 Buy	Common Stock P-Purchase	Haas Jason Chief Financial Officer	C-Suite Officer	45 344 Value: $76.0K
Sep 12, 2024 Buy	Common Stock P-Purchase	Haas Jason Chief Financial Officer	C-Suite Officer	45 344 Value: $76.0K
Sep 11, 2024 Buy	Common Stock P-Purchase	Chee Conley President & CEO	CEO / President	50 000 Value: $85.4K
Sep 11, 2024 Buy	Common Stock P-Purchase	Haas Jason Chief Financial Officer	C-Suite Officer	19 293 Value: $30.4K
Sep 11, 2024 Buy	Common Stock P-Purchase	Haas Jason Chief Financial Officer	C-Suite Officer	19 293 Value: $30.4K
Sep 11, 2024 Buy	Common Stock P-Purchase	Chee Conley President & CEO	CEO / President	50 000 Value: $85.4K
Sep 10, 2024 Buy	Common Stock P-Purchase	Chee Conley President & CEO	CEO / President	50 000 Value: $75.3K
Sep 10, 2024 Buy	Common Stock P-Purchase	Haas Jason Chief Financial Officer	C-Suite Officer	35 363 Value: $54.8K
Sep 10, 2024 Buy	Common Stock P-Purchase	Haas Jason Chief Financial Officer	C-Suite Officer	35 363 Value: $54.8K
Sep 10, 2024 Buy	Common Stock P-Purchase	Chee Conley President & CEO	CEO / President	50 000 Value: $75.3K
Jun 28, 2024 Sell	Common Stock S-Sale	Young Richard A Director	Director	34 837 Value: $178.4K
Jun 28, 2024 Sell	Common Stock S-Sale	Young Richard A Director	Director	34 837 Value: $178.4K
Jun 05, 2024 Buy	Common Stock A-Award	Simonian Nancy A Director	Director	4 000 Value: $21.2K
Jun 05, 2024 Buy	Stock Option (right to buy) A-Award	Simonian Nancy A Director	Director	6 000 Value: $31.8K
Jun 05, 2024 Buy	Common Stock A-Award	Young Richard A Director	Director	4 000 Value: $21.2K
Jun 05, 2024 Buy	Stock Option (right to buy) A-Award	Young Richard A Director	Director	6 000 Value: $31.8K
Jun 05, 2024 Buy	Common Stock A-Award	Tyson Timothy Director	Director	4 000 Value: $21.2K
Jun 05, 2024 Buy	Stock Option (right to buy) A-Award	Tyson Timothy Director	Director	6 000 Value: $31.8K
Jun 05, 2024 Buy	Stock Option (right to buy) A-Award	Dunsire Deborah Director	Director	6 000 Value: $31.8K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT SYROS PHARMACEUTICALS

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acu...

Read Full Profile Here